Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.

Slides:

Advertisements

Similar presentations

Introduction: In the setting of a suspected acute coronary syndrome (ACS), aspirin (ASA) is the primary treatment used for platelet inhibition. However,

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Aspirin Resistance Issa Majed Ghanma MD.. Platelets Function - Platelets play an important role in homeostasis. - they bind to collagen and to each other.

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.

Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.

Brar et al, JACC 2011 Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI Impact of Platelet.

Aspirinn doses in diabetics - AngiolilloSlide 1 Davide Capodanno, MD, Aasita Patel, MD, Kodlipet Dharmashankar, MD, José Luis Ferreiro, MD, Masafumi Ueno,

Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease Dominick J. Angiolillo,

Dose- and time-dependent antiplatelet effects of aspirin Christina Perneby, N. Håkan Wallén, Cathy Rooney, Desmond Fitzgerald, Paul Hjemdahl Published.

Measurement of Clopidogrel Resistance by ADP-Inhibition Does Not Reflect the Benefit of Clopidogrel on Overall Thrombotic Status Dr Diana A Gorog Consultant.

Point of Care Platelet Function Testing – Is There Still Value?

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.

Post-PCI/MI Thrombotic Events – A Plateletcentric Problem!!!!

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.

Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield, UK Stent thrombosis Future directions.

Daniel I. Simon, M.D. Associate Director, Interventional Cardiology Brigham and Women’s Hospital Associate Professor of Medicine Harvard Medical School.

Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.

Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

(The CLEAR PLATELETS-2 Study) Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation.

* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):

Aspirin Resistance. Clinical Questions How do we define aspirin resistance? Is this concept clinically relevant? Why aren’t we testing for it?

Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention Published in Journal of the American College of Cardiology.

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.

Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Marie.

David J. Moliterno, MD, MPH Chief, Cardiovascular Medicine Professor & Vice-Chair of Medicine University of Kentucky Co-Director - Gill Heart Institute.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology.

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Rossella Marcucci, MD; Anna Maria Gori, BS; Rita Paniccia, BS; Betti Giusti, BS; Serafina Valente, MD; Cristina Giglioli, MD; Piergiovanni Buonamici, MD;

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

The Use of Aspirin for Primary Prevention of Cardiovascular Diseases

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Platelet Biology and Response to Antiplatelet Therapy.

A. Mechanism of action of aspirin

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.

Sinai Center for Thrombosis Research Baltimore, Maryland, U.S.A.

Smoking Paradox for Clopidogrel : : Is It a Myth or Truth?

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Introduction We have previously reported a significant incidence of clopidogrel resistance in patients post-elective coronary stenting treated with a standard.

ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.

Oral Anticoagulation and Preventing Stent Thrombosis

Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.

ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.

Webcast May 10th, 2004 Sponsored by

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

ASA Resistance and Clinical Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Update on the New Antiplatelet Agents:

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Presenter Disclosure Information

Cardiovascular Epidemiology and Epidemiological Modelling

Presentation transcript:

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, MD

Background Diabetes is a “prothrombotic state” characterized by accelerated atherosclerosis and inflammation. Diabetic patients with acute coronary syndromes (ACS) are at higher risk for recurrent ischemic events compared to non-diabetic ACS patients. 1 Aspirin treatment in diabetic patients is less effective in inhibiting platelet thromboxane synthesis compared to aspirin treatment in non-diabetics. 2 In the primary prevention project (PPP), a higher cardiovascular risk was observed in diabetic patients on low dose aspirin compared to non-diabetic patients, suggesting that the benefits of aspirin therapy may be outweighed by aspirin insensitive mechanisms of platelet activation. 3 There are limited data quantifying the prevalence of platelet aspirin resistance in diabetic patients. No study has prospectively analyzed the effect of varying aspirin doses on platelet function in both diabetics and non-diabetics using multiple methods. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 Watala C. Blood platelet reactivity and its pharmacological modulation in people with diabetes mellitus. Current Pharmaceutical Design. 2005;11: Sacco M et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;12:

Objectives To determine whether diabetic patients with coronary artery disease during therapy with 81mg daily aspirin will exhibit a higher prevalence of aspirin resistance and a state of high platelet reactivity to multiple agonists compared to non- diabetics. To determine whether higher daily aspirin doses (162 or 325mg/day) will reduce platelet reactivity to multiple agonists and decrease the prevalence of aspirin resistance in diabetic patients.

Methods- Subjects Stable CAD outpatients (n=120) from the ASpirin-Induced Platelet EffeCT (ASPECT) study were examined. - Random double blind drug treatment sequence of 81,162, and 325mg/day for 4 weeks each over a 12 week period (Williams design). - Diabetes (n=30) was defined as fasting glucose  126mg/dL or treatment with oral hypoglycemic agents  insulin. Exclusion Criteria: -Hx of gastrointestinal bleeding, hemorrhagic stroke, illicit drug or alcohol abuse, coagulopathy or major surgery within 6 weeks prior to randomization. -Plt 4.0 mg/dL. - Current use of non-steroidal anti-inflammatory drugs, anticoagulants, or antiplatelet drugs other than aspirin.

Methods-Platelet Testing Light Transmittance Aggregometry - Maximum % change in light transmittance using platelet poor plasma as a reference. - Platelets were stimulated with 2 and 5mM arachidonic acid (AA), 5uM adenosine diphosphate (ADP) and 2ug/mL collagen. VerifyNow™ (Accumetrics, San Diego, CA) - Measures platelet aggregation to fibrinogen-coated beads after stimulation with arachidonic acid and reports this value in aspirin reaction units (ARU). PFA-100 (Dade-Behring, West Sacramento, CA) - Uses a test cartridge containing a collagen/epinephrine coated membrane to measure the closure time (seconds) required for platelets to aggregate and arrest blood flow through an aperture. Urinary 11-dehydro-TxB 2 (AspirinWorks (Denver, CO) - Levels were estimated using Enzyme Linked Immunoassay (ELISA) and reported as pg 11-dehydro-TxB 2 /mg creatinine.

Methods- Definitions Aspirin Resistance  > 20% AA-, > 70% ADP- and > 70% collagen-induced platelet aggregation. 1   550 ARU (VerifyNow).  < 193 seconds to closure (PFA-100).  Upper quartile (>420 pg 11-dehydro-TxB 2 /mg creatinine) during treatment with 81mg Gum PA et al. J Am Coll Cardiol. 2003;41: Eikelboom JW et al. Circulation 2002;105:

Patient Demographics

Results DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison Platelet Aggregation (%) mg mg mg Diabetic Non-Diabetic Diabetic Non-Diabetic 2mM AA-Induced LTA 5mM AA-Induced LTA Resistance Resistant pt #1 Resistant pt # Platelet Aggregation (%) mg mg mg mg mg mg Diabetic Non-Diabetic 2mM AA-Induced LTA5mM AA-Induced LTA Resistance Resistant pt #1 Resistant pt # mg mg mg mg mg mg Diabetic Non-Diabetic

Results DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison

Results DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison

Results DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison

Results DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison

Comparison Between Groups at Specific Dose DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison Diabetic (n=30) Non-Diabetic (n=90) Diabetic vs. Non-Diabetic (p-Value ) 81mg162mg325mg81mg162mg325mg 81 mg 162 mg 325 mg AA Stimulated Assays 2mM AA-LTA (%) 7±184±25±34±1.54±64±1 NS 5mM AA-LTA (%) 8±227±135±45±84±25±4 NS Accumetrics (ARU) 470±66448±57426±45445±48429±38428± NS Other Assays 5μm ADP-LTA (%) 64±1360±961±357±12 57±9 0.01NS0.05 2μg/mL Collagen- LTA (%) 54±2333±2129±1631±2327±2027±17 <0.001NS PFA-100 (sec.) 208±69251±67231±73226±74257±63245±65 NS Urinary Thromboxane (pg/mg creatinine) 413±110332±106302±112331±136315±145298± NS

Evaluation of Dose Effect within Groups DiabeticNon-DiabeticDiabeticNon-Diabetic Resistance (%) 81mg ASA 162mg ASA 325mg ASA * + * + * * p  0.05 for within group comparison +p  0.05 for between group comparison Diabetic (n=30) Non-Diabetic (n=90) 81mg162mg325mg81mg162mg325mg AA Stimulated Assays 2mM AA-LTA (%) 7±184±25±34±24±64±1 5mM AA-LTA (%) 8±227±135±45±84±25±4 Accumetrics (ARU) 470±66448±57426± ±48429±38*428±43 + Other Assays 5μm ADP-LTA (%) 64±1360±961±357±12 57±9 2μg/mL Collagen-LTA (%) 54±2333±21*29± ±2327±2027±17 PFA-100 (sec,) 208±69251±67*231±73226±74257±63*245±65 Urinary Thromboxane (pg/mg creatinine) 413±110332±106*302± ±136315±145298±148 * p  0.02 for 81mg vs 162 mg + p  0.02 for 81mg vs 325 mg No dose effect observed between 162mg vs 325mg

Conclusion Low dose aspirin may not provide adequate platelet inhibition in diabetic patients. In general, increasing the dose of aspirin in the diabetic patient reduces the prevalence of resistance to a level observed in the non- diabetic patient. However, we did not observe a dose dependent effect of aspirin on resistance measured by ADP-induced aggregation in diabetic patients suggesting a potential benefit of using ADP receptor blockers in addition to higher dose aspirin in selected diabetic patients. Future large scale studies are needed to evaluate the clinical efficacy of higher dose aspirin in diabetic patients. The dose dependent effects of aspirin suggest that the antithrombotic properties of the drug are not all explained by COX-1 inhibition.